Skip to main content
Nogapendekin Alfa Inbakicept-pmln Approved for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Lyn Brook
FDA Updates
The FDA has granted approval to nogapendekin alfa inbakicept-pmln (Anktiva®, Altor BioScience, LLC) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors.   Why it matters: "Patients with BCG-unresponsive NMIBC have limited...
Emerging Technologies in Therapeutics and Diagnostics
Keira Smith
Expert Analysis
By Waqas Haque, MD, MPH In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on the approval of lifileucel, the first individualized tumor-infiltrating lymphocyte therapy, for advanced melanoma; updates on the EV-302 trial of enfortumab vedotin, an antibody-drug conjugate technology; a new blood test for colorectal cancer screening from Guardant Health; the Model Facts label to guide decisions using machine learning; and more!  
Nivolumab Plus Cisplatin and Gemcitabine Approved for Unresectable or Metastatic Urothelial Carcinoma
Lyn Brook
FDA Updates
The FDA has granted approval to nivolumab (Opdivo®, Bristol Myers Squibb Company) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).   Why it matters: "The FDA approval of this combination of chemo and immune therapy represents a big step towar...
Addressing Knowledge Gaps in the Treatment of Advanced Endometrial Cancer
Lyn Brook
Practice Patterns
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the most common cancer of the female genital tract, with an estimated 67,880 new cases diagnosed and 13,250...
Enzalutamide Approved for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence
Lyn Brook
FDA Updates
The FDA has approved enzalutamide (Xtandi®, Astellas Pharma US, Inc.) for nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).   Why it matters: "Within 10 years following definitive therapy for prostate cancer, 20% to 50% of patients have BCR characterized by a ri...
Niraparib and Abiraterone Acetate Plus Prednisone Approved for BRCA-Mutated Metastatic CRPC
Lyn Brook
FDA Updates
The FDA has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega™, Janssen Biotech), plus prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (CRPC), as identified by an FDA-approved test.   Why it matters: "Metastatic CRPC remains a l...
Trifluridine and Tipiracil Plus Bevacizumab Approved for Previously Treated Metastatic Colorectal Cancer
Lyn Brook
FDA Updates
The FDA has approved trifluridine and tipiracil (Lonsurf®, Taiho Oncology, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti–vascular endothelial g...
Talazoparib Plus Enzalutamide Approved for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
Lyn Brook
FDA Updates
The FDA has approved talazoparib (Talzenna®, Pfizer, Inc.) in addition to enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer (mCRPC).   Why it matters: "Despite significant advances in the therapeutic landscape of mCRPC in recent years, currently available therapies are not curat...
i3 Health’s Survey of Urologists Reveals Key Insights Into Learning Preferences
Keira Smith
Genitourinary Cancers Data Hub News
A survey conducted by i3 Health at the Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 18 to 22, 2023, in Tucson, Arizona, has provided valuable insights into urologists' preferred formats and desired topics of continuing medical education (CME) activities, as well as the most important factors they c...
How to Counsel Genitourinary Cancer Patients About COVID-19 Vaccine Safety With Hyma Polimera, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Hyma Polimera, a Hematology/Oncology Fellow at Penn State Cancer Institute, presented her research regarding COVID-19 vaccine behaviors and outcomes among patients with genitourinary cancers. In this follow-up interview, she explains the efficacy of COVI...
Improving Gender Equity in Genitourinary Oncology Research Grants With Zain Farooq, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Zain Farooq, Hematologist/Oncologist at H. Lee Moffitt Cancer Center, presented a study investigating gender disparities in National Institutes of Health funding for genitourinary oncology research. In this follow-up interview, Dr. Farooq elaborates on the disparities experienced by women in obtaining genitourinary oncology research grants and shares the next steps for future studies addressing this issue.  
Developing Fatigue Management Guidance for Prostate Cancer Patients With Stephen Freedland, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, presented his research regarding patient perspectives on fatigue management in prostate cancer. In this follow-up interview, he elaborates on the current lack of information geared toward patients experiencing fatigue while receiving novel hormonal agents and his goal of creating guidance to fill this gap.  
Reducing Risk of Prostate Cancer Progression Through Plant-Based Diets With Vivian Liu
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Vivian Liu, Lead Clinical Research Coordinator at the University of California, San Francisco (UCSF) Osher Center for Integrative Health, presented her study investigating the association between plant-based diets and risk of disease progression in men with prostate cancer. In this follow-up interview, Ms. Liu shares additional insights into the positive health benefits of a plant-based diet for prostate cancer patients and survivors.  
Nadofaragene Firadenovec-vncg Approved for Non–Muscle-Invasive Bladder Cancer
Lyn Brook
FDA Updates
The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin®, Ferring Pharmaceuticals) for treatment of high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Nadofaragene firadenovec-vncg is a non-replicating adenoviral vector-based ge...
Knowledge Gained for Treatment of Metastatic Hormone-Sensitive Prostate Cancer
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnose...
Darolutamide Approved for Treatment of Metastatic Hormone-Sensitive Prostate Cancer
Lyn Brook
FDA Updates
The FDA has approved darolutamide (Nubeqa®, Bayer HealthCare Pharmaceuticals Inc.) in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). "Standard treatment for patients with metastatic, hormone-sensitive prostate cancer includes the addition of either docetaxel or an androgen-receptor pathway i...
Closing Nurses’ Knowledge Gaps Regarding Treatment of Castration-Resistant Prostate Cancer
Lyn Brook
Practice Patterns
An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new ca...